22nd Century Group Warrant Exchange Eliminates 93% of

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
22nd Century Group Warrant Exchange Eliminates 93% of Warrant Liability

Company Continues Paving the Way to Up-List to a National Securities Exchange

22nd Century Group, Inc. (OTCQB:XXII) today announced that the Company’s warrant exchange, which concluded last Thursday, was a huge success greatly exceeding management’s expectations. The warrant exchange reduced 22nd Century Group’s “derivative warrant liability” by 93 percent and generated gross proceeds of approximately $3.6 million for the Company.

As reported last month, the primary purpose of the warrant exchange was to reduce 22nd Century Group’s “derivative warrant liability” through the exercise or amendment of the Company’s outstanding warrants in order for the Company to have sufficient stockholders’ equity to up-list its common stock to a national securities exchange – such as NASDAQ or NYSE. Many institutional investors and retail brokers looking to build a position in 22nd Century Group stock cannot buy OTC Bulletin Board stocks.

As of December 13, 2013, 22nd Century Group had total assets of approximately $12 million, which includes approximately $6.2 million in cash, and only $700 thousand in current liabilities. The Company’s only long-term liability is its “derivative warrant liability,” which due to the warrant exchange has been reduced from $18.6 million to approximately $1.2 million.

22nd Century Group’s $6.2 million cash balance reflects $3.2 million the Company has already invested and paid in full for the equipment at its manufacturing facility. As reported in early December, the Company’s management believes that having its own factory will create tremendous shareholder value since costs will be reduced and control, production and exports of its differentiated tobacco products will be greatly facilitated.

John Brodfuehrer, 22nd Century’s Group’s CFO, stated, “We now have approximately $10 million of net stockholders’ equity, which is more than sufficient to qualify for an up-listing to a national securities exchange.”

22nd Century Group currently has 56,691,897 shares of common stock issued and outstanding, including the approximate 5.5 million shares the Company issued as a result of the warrant exchange. Approximately 5.3 million shares of common stock issued from the warrant exchange were from the exercise of warrants on a cash basis. These shares cannot be sold for 6 months pursuant to Rule 144.

The Company currently has approximately 10.6 million warrant shares outstanding. Of these, 6.25 million have a purchase price of $1.96 to $2.40 and 4.1 million are owned by the Company’s management.

The Company’s Series-A warrant holder, which is an institutional investor, has only 225,798 warrant shares remaining, as compared to approximately 3.67 million warrant shares as of September 30, 2013. There are no Series-B or Series-C warrants outstanding.

Joseph Pandolfino, Founder and CEO of 22nd Century’s Group stated, “We are now well positioned to up-list to a national securities exchange; the only qualification remaining is our share price which we expect to appreciate over the next 60 days since many catalysts are on the horizon as we continue to execute our business plan.”

Chardan Capital Markets, LLC acted as the financial advisor for 22nd Century Group’s warrant exchange.

For additional information, please visit: www.xxiicentury.com

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 114 issued patents in 78 countries plus an additional 36 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potential less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2012, filed on March 18, 2013, including the section entitled “Risk Factors,” and our other reports filed with the U.S Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.



Redington, Inc.
Tom Redington, 203-222-7399
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vylor's $3 Billion Buyback: A Long-Term Bet

Updated Category News Views 7

Pumping Confidence with a Massive Buyback Vylor's big move to throw $3 billion into a share buyback isn't about short-term antics. This company's doubling down on long-term value creation, making sure every stakeholder knows they're in for the long haul. It's a gutsy move but what this step really tells us is, they've got faith in the business and a balance sheet that can...

Continue Reading
Anavex Faces Securities Lawsuit: Investor Implications

Updated Category News Views 0

Storm Clouds Over Anavex: What Investors Need to Know If you've got a slice of Anavex Life Sciences Corp. (NASDAQ: AVXL) in your portfolio, the latest chapter of their legal saga feels less like a twist and more like a twist of the knife. These lawsuits often come out of left field for investors, but this one seems like a slow train that’s been gathering steam for a...

Continue Reading
Tigo Energy Faces Class Action Over Revenue Claims

Updated Category News Views 4

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

Continue Reading
WOLFX Super App Surges with 300% Growth Post-Launch

Updated Category News Views 4

A Fast-Paced Entry into the College Scene College life isn’t getting any easier, but the WOLFX app is blazing a trail through U.S. campuses, promising to mend some of the chaos students deal with daily. It's barely taken a breath since launching just a month ago, already knitting itself into the routine of students from 104 universities in 130 cities across America -...

Continue Reading
FuelCell's Class Action: Investors' Deadline Approaching

Updated Category News Views 3

One Rough Ride for FuelCell Investors Sometimes the market feels like a roller coaster stuck on the down-hill plunge, and right now, FuelCell Energy (NASDAQ: FCEL) investors are gripping their harnesses. The latest turmoil has investors looking at a tight November 10 deadline to decide if they want in on the securities class action shaking the ground beneath FCEL. Looming...

Continue Reading
Beyond The Bounce Expands with Pro Pickleball Star

Updated Category News Views 1

Pickleball's Power Play: The Media Move Out of the blue, the world of niche sports finds its hub. Beyond The Bounce steps up to the plate by roping in pickleball’s own Zane Navratil. The hype’s not in the spin here—this is serious business. The company plans to push the boundaries of the sport into mainstream media, or at least give it a decent shot. Zane Navratil:...

Continue Reading
HSG's Laser Tech Dazzles at FABTECH 2026

Updated Category News Views 1

Laser Innovations on Display at FABTECH 2026 Listen up, folks—FABTECH 2026 in Vegas is where HSG Laser decided to flaunt their new toys, codenamed TS2 PRO and the mystical AI CutPilot. Now, unless you've been living under a rock, you'll know HSG is all about shaking up the laser cutting scene. They've done it for two decades, and now they're pushing the envelope with...

Continue Reading
Volvo's Q3 2026 Results: Strong Growth and Margin

Updated Category News Views 4

Volvo Group's Robust Q3 Performance It's not every day that you see a company like Volvo Group churning out results that make you take a second sip of that morning coffee. But here we are—looking at Q3 2026 with growth numbers that pack a punch. You can't argue with SEK 119.5 billion in net sales, especially when organic sales growth hit 7%. That's no small feat in...

Continue Reading
Harbour BioMed's Batoclimab Injected Into Myasthenia Market

Updated Category News Views 6

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

Continue Reading
3Srobotics Breaks Ground with North American Debut

Updated Category News Views 2

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
class="blog__more"> More News Articles